Treeline Biosciences

Treeline Biosciences is a private, preclinical-stage biotech with an ambitious model to reliably develop medicines for hard-to-treat diseases. Co-founded by experienced medical oncologists Josh Bilenker and Jeff Engelman, the company leverages a fully integrated, in-house discovery platform combining biology, chemistry, protein science, and computation to tackle undruggable targets. With a target-centric pipeline and operations in the U.S. and Europe, Treeline aims to advance only the most promising candidates into human testing, seeking to redefine treatment in oncology and beyond.

Integrated drug discovery platform combining in-house expertise in multiple modalities (small molecule inhibitors, protein degraders, antibody-drug conjugates) with a closed-loop system of computational modeling, machine learning, and experimental biology to target historically undruggable proteins.

Treeline operates in the highly competitive field of next-generation small molecule drug discovery, competing with both large pharmaceutical companies and nimble biotechs focused on protein degradation, molecular glues, and covalent inhibitors. Its differentiation lies in its integrated, multi-modal in-house platform and its leadership's proven track record in oncology drug development.